Genome-wide association studies suggest limited immune gene enrichment in schizophrenia compared to 5 autoimmune diseases

Schizophrenia Bulletin

Volumn 42, Issue 5, 2016, Pages 1176-1184

  Pouget, Jennie G ^a,b,c   Gonçalves, Vanessa F ^a,c   Spain, Sarah L ^d,e   Finucane, Hilary K ^f,g   Raychaudhuri, Soumya ^h,i,j,k   Kennedy, James L ^a,b,c   Knight, Jo ^a,b,c,l  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^e KING'S COLLEGE LONDON   (United Kingdom)

^f MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^g HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^h HARVARD MEDICAL SCHOOL   (United States)

ⁱ BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^j LABORATORY FOR MOLECULAR MEDICINE   (United States)

^k UNIVERSITY OF MANCHESTER   (United Kingdom)

^l LANCASTER UNIVERSITY   (United Kingdom)

more..

Author keywords

Autoimmune; Immune; Inflammation; Inflammatory; Schizophrenia genetic

Indexed keywords

CHAPERONIN 60; CLU PROTEIN; DPP4 PROTEIN; EARLY GROWTH RESPONSE FACTOR 1; ESAM PROTEIN; NFATC3 PROTEIN; PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BENCHMARKING; BRAIN DEVELOPMENT; CLINICAL EVALUATION; COMPARATIVE STUDY; CROHN DISEASE; GENE IDENTIFICATION; GENE LOCUS; GENOME-WIDE ASSOCIATION STUDY; HUMAN; IMMUNE RESPONSE; IMMUNOGENETICS; IMMUNOTHERAPY; MAJOR HISTOCOMPATIBILITY COMPLEX; MULTIPLE SCLEROSIS; NERVE CELL PLASTICITY; NULL ALLELE; PLEIOTROPY; PRIORITY JOURNAL; PSORIASIS; RHEUMATOID ARTHRITIS; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; ULCERATIVE COLITIS; AUTOIMMUNE DISEASE; GENETICS; IMMUNOLOGY;

AUTOIMMUNE DISEASES; GENOME-WIDE ASSOCIATION STUDY; HUMANS; SCHIZOPHRENIA;

EID: 85020267374     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbw059     Document Type: Article

References (54)

1. Sullivan PF, Kendler KS, Neale MC. Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies. Arch Gen Psychiatry. 2003;60:1187-1192.
2. Schizophrenia Working Group of the Psychiatric Genomics Consortium. Biological insights from 108 schizophreniaassociated genetic loci. Nature. 2014;511:421-427.
3. Fessel WJ. Blood proteins in functional psychoses. A review of the literature and unifying hypothesis. Arch Gen Psychiatry. 1962;6:132-148.
4. Heath RG, Krupp IM. Schizophrenia as an immunologic disorder. I. Demonstration of antibrain globulins by fluorescent antibody techniques. Arch Gen Psychiatry. 1967;16:1-9.
5. Mednick SA, Machon RA, Huttunen MO, Bonett D. Adult schizophrenia following prenatal exposure to an influenza epidemic. Arch Gen Psychiatry. 1988;45:189-192.
6. Beumer W, Gibney SM, Drexhage RC, et al. The immune theory of psychiatric diseases: a key role for activated microglia and circulating monocytes. J Leukoc Biol. 2012;92:959-975.
7. Huh GS, Boulanger LM, Du H, Riquelme PA, Brotz TM, Shatz CJ. Functional requirement for class I MHC in CNS development and plasticity. Science. 2000;290:2155-2159.
8. Stellwagen D, Malenka RC. Synaptic scaling mediated by glial TNF-alpha. Nature. 2006;440:1054-1059.
9. Schafer DP, Lehrman EK, Kautzman AG, et al. Microglia sculpt postnatal neural circuits in an activity and complement-dependent manner. Neuron. 2012;74:691-705.
10. Bialas AR, Stevens B. TGF-β signaling regulates neuronal C1q expression and developmental synaptic refinement. Nat Neurosci. 2013;16:1773-1782.
11. Gallagher D, Norman AA, Woodard CL, et al. Transient maternal IL-6 mediates long-lasting changes in neural stem cell pools by deregulating an endogenous self-renewal pathw a y. Cell Stem Cell. 2013;13:564-576.
12. Smith SE, Li J, Garbett K, Mirnics K, Patterson PH. Maternal immune activation alters fetal brain development through interleukin-6. J Neurosci. 2007;27:10695-10702.
13. Short SJ, Lubach GR, Karasin AI, et al. Maternal influenza infection during pregnancy impacts postnatal brain development in the rhesus monkey. Biol Psychiatry. 2010;67:965-973.
14. Khandaker GM, Zimbron J, Dalman C, Lewis G, Jones PB. Childhood infection and adult schizophrenia: a meta-analysis of population-based studies. Schizophr Res. 2012;139:161-168.
15. Pearlman DM, Najjar S. Meta-analysis of the association between N-methyl-D-aspartate receptor antibodies and schizophrenia, schizoaffective disorder, bipolar disorder, and major depressive disorder. Schizophr Res. 2014;157:249-258.
16. Benros ME, Pedersen MG, Rasmussen H, Eaton WW, Nordentoft M, Mortensen PB. A nationwide study on the risk of autoimmune diseases in individuals with a personal or a family history of schizophrenia and related psychosis. Am J Psychiatry. 2014;171:218-226.
17. Miller BJ, Buckley P, Seabolt W, Mellor A, Kirkpatrick B. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry. 2011;70:663-671.
18. Fillman SG, Cloonan N, Catts VS, et al. Increased inflammatory markers identified in the dorsolateral prefrontal cortex of individuals with schizophrenia. Mol Psychiatry. 2013;18:206-214.
19. Miller AH, Raison CL. Are anti-inflammatory therapies viable treatments for psychiatric disorders?: where the rubber meets the road. JAMA Psychiatry. 2015;72:527-528.
20. Sommer IE, van Westrhenen R, Begemann MJ, de Witte LD, Leucht S, Kahn RS. Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: an update. Schizophr Bull. 2014;40:181-191.
21. Girgis RR. Tocilizumab as add-on treatment for residual positive, negative, and cognitive symptoms of schizophrenia. ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine (US).
22. Horváth S, Mirnics K. Immune system disturbances in schizophrenia. Biol Psychiatry. 2014;75:316-323.
23. Haack M, Hinze-Selch D, Fenzel T, et al. Plasma levels of cytokines and soluble cytokine receptors in psychiatric patients upon hospital admission: effects of confounding factors and diagnosis. J Psychiatr Res. 1999;33:407-418.
24. Stefansson H, Ophoff RA, Steinberg S, et al. Common variants conferring risk of schizophrenia. Nature. 2009;460:744-747.
25. Debnath M, Cannon DM, Venkatasubramanian G. Variation in the major histocompatibility complex [MHC] gene family in schizophrenia: associations and functional implications. Prog Neuropsychopharmacol Biol Psychiatry. 2013;42:49-62.
26. Jia P, Wang L, Meltzer H Y, Zhao Z. Common variants conferring risk of schizophrenia: a pathway analysis of GWAS data. Schizophr Res. 2010;122:38-42.
27. Network and Pathway Analysis Subgroup of the Psychiatric Genomics Consortium. Psychiatric genome-wide association study analyses implicate neuronal, immune and histone pathways. Nat Neurosci 2015;18:199-209.
28. Franke A, McGovern DP, Barrett JC, et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet. 2010;42:1118-1125.
29. Sawcer S, Hellenthal G, Pirinen M et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011;476:214-219.
30. Strange A, Capon F, Spencer CC et al. A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. Nat Genet 2010;42:985-990.
31. Stahl EA, Raychaudhuri S, Remmers EF, et al. Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. Nat Genet. 2010;42:508-514.
32. Anderson CA, Boucher G, Lees CW, et al. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet. 2011;43:246-252.
33. ∗01:03 in inflammatory bowel diseases and heterozygous advantage in ulcerative colitis. Nat Genet. 2015;47:172-179.
34. Tsoi LC, Spain SL, Knight J, et al. Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. Nat Genet. 2012;44:1341-1348.
35. Raychaudhuri S, Korn JM, McCarroll SA, et al. Accurately assessing the risk of schizophrenia conferred by rare copynumber variation affecting genes with brain function. PLoS Genet. 2010;6:e1001097.
36. Finucane H. Partitioning heritability by functional category using GWAS summary statistics. bioRxiv. 2015; doi:10.1101/014241.
37. Altshuler DM, Gibbs RA, Peltonen L et al. Integrating common and rare genetic variation in diverse human populations. Nature 2010;467:52-58.
38. Wang K, Li M, Hakonarson H. Analysing biological pathways in genome-wide association studies. Nat Rev Genet. 2010;11:843-854.
39. Mukherjee S, Ripke S, Andreassen O et al. Parsing genetic associations in the MHC in schizophrenia. Presented at 22nd World Congress of Psychiatric Genetics, Copenhagen, Denmark, 15 October 2014.
40. Sekar A, Bialas AR, de Rivera H, et al. Schizophrenia risk from complex variation of complement component 4. Nature 2016;530:177-183.
41. Fromer M, Pocklington AJ, Kavanagh DH, et al. De novo mutations in schizophrenia implicate synaptic networks. Nature. 2014;506:179-184.
42. O'Roak BJ, Stessman HA, Boyle EA, et al. Recurrent de novo mutations implicate novel genes underlying simplex autism risk. Nat Commun. 2014;5:5595.
43. Hamdan FF, Gauthier J, Spiegelman D, et al. Mutations in SYNGAP1 in autosomal nonsyndromic mental retardation. N Engl J Med. 2009;360:599-605.
44. Sun L, Craiu RV, Paterson AD, Bull SB. Stratified false discovery control for large-scale hypothesis testing with application to genome-wide association studies. Genet Epidemiol. 2006;30:519-530.
45. Cross-Disorder Group of the Psychiatric Genomics Consortium. Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nat Genet 2013;45:984-994.
46. Hawrylycz MJ, Lein ES, Guillozet-Bongaarts AL, et al. An anatomically comprehensive atlas of the adult human brain transcriptome. Nature. 2012;489:391-399.
47. Magen D, Georgopoulos C, Bross P, et al. Mitochondrial hsp60 chaperonopathy causes an autosomal-recessive neurodegenerative disorder linked to brain hypomyelination and leukodystrophy. Am J Hum Genet. 2008;83:30-42.
48. Jones MW, Errington ML, French PJ, et al. A requirement for the immediate early gene Zif268 in the expression of late LTP and long-term memories. Nat Neurosci. 2001;4:289-296.
49. Nasdala I, Wolburg-Buchholz K, Wolburg H, et al. A transmembrane tight junction protein selectively expressed on endothelial cells and platelets. J Biol Chem. 2002;277:16294-16303.
50. Gómez-Sintes R, Lucas JJ. NFAT/Fas signaling mediates the neuronal apoptosis and motor side effects of GSK-3 inhibition in a mouse model of lithium therapy. J Clin Invest. 2010;120:2432-2445.
51. Han BH, DeMattos RB, Dugan LL, et al. Clusterin contributes to caspase-3-independent brain injury following neonatal hypoxia-ischemia. Nat Med. 2001;7:338-343.
52. Stessman HA, Bernier R, Eichler EE. A genotype-first approach to defining the subtypes of a complex disease. Cell. 2014;156:872-877.
53. Ripke S, O'Dushlaine C, Chambert K, et al. Genome-wide association analysis identifies 13 new risk loci for schizophrenia. Nat Genet. 2013;45:1150-1159.
54. Canetta S, Sourander A, Surcel HM, et al. Elevated maternal C-reactive protein and increased risk of schizophrenia in a national birth cohort. Am J Psychiatry. 2014;171:960-968.